What Is CJC-1295? A Clear Guide to the Long Acting GHRH Analog

How CJC-1295 Works

Growth hormone release is governed by two signals from the hypothalamus, a small region at the base of the brain. GHRH tells the pituitary gland to release growth hormone, and a second hormone, somatostatin, acts as the brake. The balance between the two produces the bursts of growth hormone the body releases through the day and night.

CJC-1295 copies the first 29 amino acids of natural GHRH, the stretch of the molecule that carries its activity. It binds the same GHRH receptors on the pituitary, and when it does, the pituitary releases growth hormone that it made itself. That growth hormone then travels to the liver and other tissues, where it drives production of IGF-1 (insulin like growth factor 1), the hormone responsible for many of growth hormone's effects on tissue.

The chain from GHRH to growth hormone to IGF-1 is usually called the growth hormone axis, and every CJC-1295 study measures its effect at points along that chain. Because the drug acts at the top of the chain, the body's normal checks stay in place. Rising IGF-1 signals back to the brain, and somatostatin can still hold release back. Injecting growth hormone directly works differently, because it skips the pituitary altogether.

This upstream action is also why CJC-1295 is often discussed alongside peptides that raise growth hormone through a different receptor, such as ipamorelin. No published human trial has tested CJC-1295 in combination with another peptide, so any pairing rests on reasoning about mechanism rather than on measured results.

What DAC Does and Why the Half Life Matters

Natural GHRH is broken down by enzymes in the blood within minutes, which is why the body releases it in short pulses. CJC-1295 was designed to last far longer, and it does this in two ways. First, four of its amino acids are swapped for versions that enzymes have a harder time cutting. Second, it carries DAC, short for Drug Affinity Complex, a reactive chemical group that lets the peptide attach itself to albumin, the most common protein in blood, shortly after injection.

Albumin circulates for weeks, so a peptide bound to it is shielded from rapid breakdown and slowly released. In early laboratory work, researchers showed that the DAC version bound to albumin and remained in the blood of rats for more than 72 hours. In people, the measured half life was 5.8 to 8.1 days, meaning it takes roughly a week for the amount in the blood to fall by half.

Most of what a complete overview of CJC-1295 therapy has to explain follows from this one design choice. A long half life is the reason injections can be spaced out instead of given daily, and it is the main practical difference between CJC-1295 and older GHRH drugs. Half life describes how long the drug stays in the blood, though. It says nothing on its own about whether a person will notice any change in how they look or feel.

CJC-1295 With DAC vs Without DAC

Two different products are sold under the CJC-1295 name, and the difference matters. The version with DAC is the one described above. It is also the version tested in the published human trials.

The version without DAC is often called modified GRF (1 to 29). It keeps the enzyme resistant amino acid swaps but has no albumin attachment, so it is cleared from the blood far faster, much closer to the timing of natural GHRH. Published human data on this version are very limited, and the half life and hormone figures from the DAC trials do not apply to it.

Because pharmacies and websites often use the two names interchangeably, it is worth asking your prescriber exactly which form is being discussed. Whether either form fits your situation is part of the wider question of choosing between CJC-1295 and other peptide options, a decision a prescriber makes with your full history in front of them.

Does CJC-1295 Keep Natural Growth Hormone Pulses?

In healthy people, growth hormone is not released at a steady rate. It comes in bursts, with the largest usually arriving during deep sleep. A reasonable worry about a drug that lasts a week is that it might flatten those bursts into a constant level, which is not how the body normally works.

Researchers tested this directly. In a study that sampled blood every 20 minutes overnight, healthy men aged 20 to 40 were tested before and one week after a single dose of 60 or 90 micrograms per kilogram. Their growth hormone still came in distinct pulses, and the number and size of those pulses did not change. What changed was the level between pulses, which rose about 7.5 fold, lifting average growth hormone by 46 percent and IGF-1 by 45 percent.

This finding contradicts a claim that is common online, that CJC-1295 replaces natural pulses with a flat, sustained level. On the evidence available, the pulse pattern was preserved. The study was small and short, so it does not show what happens with months of use.

What the Human Evidence Covers and What It Does Not

The core human research was two placebo controlled trials lasting 28 and 49 days. Healthy adults aged 21 to 61 received either a single injection or two to three injections given weekly or every other week. After one dose, average growth hormone rose 2 to 10 fold and stayed raised for 6 days or more, while IGF-1 rose 1.5 to 3 fold and stayed raised for 9 to 11 days. After repeated doses, IGF-1 stayed above its starting level for up to 28 days. The researchers reported no serious adverse reactions and found doses of 30 or 60 micrograms per kilogram the best tolerated.

A few other studies fill in the picture. A small study of 11 healthy young men tracked changes in blood proteins that act as markers of growth hormone activity, and found measurable shifts after CJC-1295. In mice bred without the gene for GHRH, once daily CJC-1295 restored normal growth, which confirmed the drug can stand in for the missing signal in animals. Neither finding tells us how people feel or look on the drug.

Taken together, the key clinical studies on CJC-1295 involve a small number of healthy volunteers followed for weeks, not years. They answer one question well: CJC-1295 raises growth hormone and IGF-1, and for how long. They do not measure fat loss, muscle gain, strength, sleep, energy, recovery, skin, mood or aging. No study has tracked long term safety.

Much of what is written about CJC-1295 online borrows results from other drugs, such as injected growth hormone or tesamorelin, a different GHRH drug approved for a specific condition. Those results cannot be transferred to CJC-1295, because the drugs differ in structure, dose and how long they act. That gap is the reason any honest account of CJC-1295 benefits has to separate what was measured from what people describe.

CJC-1295 at a Glance

The table below gathers the main facts from the published research in one place, with the source behind each one.

Regulatory Status and Safety History

CJC-1295 is not approved by the FDA for any medical use. It was nominated for the FDA's list of bulk drug substances that pharmacies may compound, placed in a category of substances that may present significant safety risks, and the nomination was later withdrawn. In that review, the FDA identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and noted that clinical data are limited.

Development of the drug as a treatment also hit a setback. A Phase II trial in people with HIV related fat redistribution was halted in 2006 after a participant died, a death that was attributed to heart disease. No later trial has established CJC-1295 for any condition.

In the human studies, the side effects reported most often were reactions at the injection site, flushing and headache. Because CJC-1295 raises growth hormone, effects linked to higher growth hormone are also possible, including fluid retention, joint aches, tingling in the hands and changes in blood sugar. Those reports, along with the people who should not use it, shape the CJC-1295 side effects and safety picture a prescriber reviews before writing a prescription.

For athletes, the answer is simple. The World Anti Doping Agency prohibits GHRH and its analogs at all times, both in and out of competition, and CJC-1295 falls within that ban.

It helps to compare this record with sermorelin, an older and shorter acting GHRH drug. Sermorelin was approved by the FDA as Geref in 1997 for children with growth hormone deficiency, and the Federal Register records that it was later withdrawn for reasons other than safety. That approval history is one of the clearest differences between CJC-1295 and sermorelin.

How Physician Supervised Access Works

CJC-1295 is available only by prescription, at a licensed physician's discretion. The process starts with an online health questionnaire. A licensed physician reviews your answers and history, may ask for lab work, and then decides whether CJC-1295 is appropriate for you at all. If it is prescribed, the medication is dispensed by our pharmacy partner and shipped to you.

There is no standard dose of CJC-1295. The human studies used amounts based on body weight, from 30 to 90 micrograms per kilogram, given once or repeated weekly or every other week. Because of that, how CJC-1295 dosing is decided comes down to your prescriber, who also chooses the form and schedule and decides what monitoring you need.

The review happens online rather than in an office, a model with tradeoffs worth weighing against in clinic versus telehealth peptide care. Whichever route you take, the physician's job is the same: to weigh the limited evidence against your goals and risks. Hearing how clinicians weigh limited peptide evidence in their own practice can help you prepare questions before your review.

Conclusion

CJC-1295 is a long acting version of GHRH that prompts the pituitary to release more of the body's own growth hormone. Its DAC attachment keeps it in the blood for about a week, and in healthy adults a single dose raised growth hormone for 6 days or more and IGF-1 for 9 to 11 days, while natural pulses were preserved.

That is where the evidence stops. Effects on body composition, sleep, energy, recovery and aging have not been measured, long term safety is unknown, the FDA has not approved the drug, and it is banned in sport. Anyone considering it should do so with a physician who can review their health history, explain the gaps honestly and decide whether it is appropriate.

If you want a licensed physician to review whether CJC-1295 is right for you, start your intake.